by Stacey Johnson | Jun 16, 2023
The definition of a rare disease in the U.S. is under 200,000 patients. The 10 per cent of Americans living with a rare disease is equivalent to 30 million people. Put another way, that is close to the entire population of Canada (at 39 million). There are 7,000 –...
by Cal Strode | Jan 5, 2023
In 2022, the UK’s Cell and Gene Therapy Catapult (aka CGT Catapult) celebrated its tenth anniversary (congratulations!) marking 10 years of accelerating innovation in cell and gene therapies (CGTs) in the UK. Much like CCRM, CGT Catapult was established as an...
by Stacey Johnson | Nov 25, 2022
If manufacturing is the gatekeeper to success in the cell and gene therapy space, it’s not surprising that the topic regularly comes up when industry leaders come together to discuss the future or to tackle the challenges we face in commercializing cell and gene...
by Stacey Johnson | Sep 30, 2022
After returning from CellCAN’s 2022 Strategic Forum in Ottawa, Ontario, where Canada’s cell and gene therapy biomanufacturing community came together to share information and network, it is clear that the country’s biomanufacturing landscape is improving. As I and...
by Cal Strode | Sep 15, 2022
OmniaBio Inc., a subsidiary of CCRM, is building the largest facility of its kind in Canada, providing specialized manufacturing to the flourishing cell and gene therapy (CGT) industry. The new contract development and manufacturing organization (CDMO) will focus on...
Comments